Invesco Ltd. Has $13.36 Million Holdings in ANI Pharmaceuticals, Inc. $ANIP

Invesco Ltd. boosted its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 1.0% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 199,567 shares of the specialty pharmaceutical company’s stock after acquiring an additional 2,022 shares during the quarter. Invesco Ltd. owned 0.92% of ANI Pharmaceuticals worth $13,361,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. National Bank of Canada FI acquired a new stake in ANI Pharmaceuticals during the 1st quarter worth about $79,000. GAMMA Investing LLC boosted its position in ANI Pharmaceuticals by 163.8% during the 1st quarter. GAMMA Investing LLC now owns 1,419 shares of the specialty pharmaceutical company’s stock worth $95,000 after acquiring an additional 881 shares during the period. Rafferty Asset Management LLC acquired a new stake in ANI Pharmaceuticals during the 4th quarter worth about $200,000. Bridgefront Capital LLC acquired a new position in ANI Pharmaceuticals in the 4th quarter worth about $204,000. Finally, Mesirow Financial Investment Management Inc. acquired a new position in ANI Pharmaceuticals in the 1st quarter worth about $206,000. 76.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at ANI Pharmaceuticals

In related news, Director Matthew J. Leonard sold 6,937 shares of the business’s stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $88.17, for a total transaction of $611,635.29. Following the completion of the transaction, the director owned 9,392 shares of the company’s stock, valued at approximately $828,092.64. The trade was a 42.48% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jeanne Thoma sold 21,540 shares of the business’s stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $89.15, for a total value of $1,920,291.00. Following the transaction, the director directly owned 23,405 shares of the company’s stock, valued at $2,086,555.75. This represents a 47.93% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 401,247 shares of company stock worth $35,300,435 in the last 90 days. Insiders own 11.10% of the company’s stock.

ANI Pharmaceuticals Stock Performance

ANIP opened at $91.01 on Friday. The company has a market cap of $1.97 billion, a PE ratio of -118.19 and a beta of 0.61. The stock has a 50-day moving average of $70.63 and a 200-day moving average of $65.91. ANI Pharmaceuticals, Inc. has a 52-week low of $52.50 and a 52-week high of $92.53. The company has a debt-to-equity ratio of 1.39, a quick ratio of 1.96 and a current ratio of 2.54.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings results on Friday, August 8th. The specialty pharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.42 by $0.38. The company had revenue of $211.37 million during the quarter, compared to the consensus estimate of $187.18 million. ANI Pharmaceuticals had a positive return on equity of 25.03% and a negative net margin of 1.37%.The firm’s revenue was up 53.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.02 EPS. As a group, equities research analysts forecast that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on ANIP. Guggenheim reaffirmed a “buy” rating and issued a $86.00 target price on shares of ANI Pharmaceuticals in a research report on Monday, May 12th. Piper Sandler reaffirmed an “overweight” rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Friday, August 8th. HC Wainwright reaffirmed a “buy” rating and issued a $93.00 target price (up from $84.00) on shares of ANI Pharmaceuticals in a research report on Friday, August 8th. Wall Street Zen raised ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 16th. Finally, Truist Financial upped their target price on ANI Pharmaceuticals from $65.00 to $77.00 and gave the stock a “hold” rating in a research report on Monday, August 11th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $84.75.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.